



Xavier Levac
Core Facility Manager

The Unit for Innovative Therapies (UIT) is a clinical core facility that allows research teams to conduct projects requiring monitoring of participants ranging from a few hours to several days.

It is a secure facility for the administration of cellular, genetic and biological therapies.

Its goal: to offer patients in therapeutic failure the most advanced treatment options in oncology, neurology, immunopathology and cardiometabolic, including therapies that are being administered to humans for the first time.

SERVICES

PHASE 1 CLINICAL TRIALS: TURNKEY SERVICE

- Complete management of clinical and administrative aspects of phase 1 clinical trials, from startup to closure.

PHASE 2 AND 3 CLINICAL TRIALS

- Project management services (non-exhaustive list): confidentiality agreement and feasibility process; selection visit; evaluation of institutional suitability; drafting and/or revising consent forms; negotiating budgets; sponsor visit; clinical data management
- When the project is initiated by a CHUM researcher, the following services are also offered: project startup and management; monitoring; clinical services and laboratory services

CONTINUING EDUCATION

- Basic Life Support (BLS)
- Advanced Cardiac Life Support (ACLS)

RESEARCH IN ACTION

In August 2022, a lung cancer patient was treated in a clinical trial of immunotherapy based on tumour infiltrating lymphocytes (TIL therapy).

The CHUM is the **1st hospital centre in Quebec** to have administered a patient's own tumour infiltrating lymphocyte T cells or "TILs" as part of a lung cancer clinical trial.

HIGHLIGHTS

Since June 2019, the UIT has been on the front lines of early clinical research and has followed the standards of a world-class clinical research centre.

Our **16-bed** secure unit is staffed by a team of **40 people** and is a major player in therapeutic innovation.

Since 2019, our core facility:



Can rely on **57** investigators to conduct phase 1 and 2 clinical studies



Hosted more than **110 clinical studies**, of which about ¾ were in collaboration with pharmaceutical companies

